In-vivo longitudinal MRI study: an assessment of melanoma brain metastases in a clinically relevant mouse model. by Henry, Mariama N et al.
Western University
Scholarship@Western
Medical Biophysics Publications Medical Biophysics Department
4-1-2015
In-vivo longitudinal MRI study: an assessment of
melanoma brain metastases in a clinically relevant
mouse model.
Mariama N Henry
Yuhua Chen
Catherine D McFadden
Felicia C Simedrea
Paula J Foster
Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub
Part of the Medical Biophysics Commons
Citation of this paper:
Henry, Mariama N; Chen, Yuhua; McFadden, Catherine D; Simedrea, Felicia C; and Foster, Paula J, "In-vivo longitudinal MRI study:
an assessment of melanoma brain metastases in a clinically relevant mouse model." (2015). Medical Biophysics Publications. 68.
https://ir.lib.uwo.ca/biophysicspub/68
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
In-vivo longitudinal MRI study: an assessment of melanoma
brain metastases in a clinically relevant mouse model
Mariama N. Henrya,b, Yuhua Chena, Catherine D. McFaddena,
Felicia C. Simedreac and Paula J. Fostera,b
Brain metastases are an important clinical problem. Few
animal models exist for melanoma brain metastases; many
of which are not clinically relevant. Longitudinal MRI was
implemented to examine the development of tumors in
a clinically relevant mouse model of melanoma brain
metastases. Fifty thousand human metastatic melanoma
(A2058) cells were injected intracardially into nude mice.
Three Tesla MRI was performed using a custom-built
gradient insert coil and a mouse solenoid head coil. Imaging
was performed on consecutive days at four time points.
Tumor burden and volumes of metastases were measured
from balanced steady-state free precession image data.
Metastases with a disrupted blood–tumor barrier were
identified from T1-weighted spin echo images acquired
after administration of gadopentetic acid (Gd-DTPA).
Metastases permeable to Gd-DTPA showed signal
enhancement. The number of enhancing metastases was
determined by comparing balanced steady-state free
precession images with T1-weighted spin echo images.
After the final imaging session, ex-vivo permeability and
histological analyses were carried out. Imaging showed that
both enhancing and nonenhancing brain metastases
coexist in the brain, and that most metastases switched
from the nonenhancing to the enhancing phenotype. Small
numbers of brain metastases were enhancing when first
detected by MRI and remained enhancing, whereas other
metastases remained nonenhancing to Gd-DTPA
throughout the experiment. No clear relationship existed
between the permeability of brain metastases and size,
brain location and age. Longitudinal in-vivo MRI is key to
studying the complex and dynamic processes of metastasis
and changes in the blood–tumor barrier permeability, which
may lead to a better understanding of the variable
responses of brain metastases to treatments. Melanoma
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Introduction
A common complication among patients with malignant
melanoma is metastasis to the brain [1,2]. Patients with
metastatic melanoma have a 40–60% risk of developing
brain metastases [3]. Autopsy series reports have shown an
incidence of melanoma brain metastasis ranging from 17.5
to greater than 90% [3–6]. Compared with other primary
tumors such as lung and breast cancer, melanoma has a
greater tendency to metastasize to the brain [3,7]. The
prognosis for patients with melanoma brain metastasis
remains dismal, with a median survival of 1–2 months
without treatment [8–10] and 4–6 months with treatment
[8,11], and a 1-year survival rate in less than 13% of patients
[12]. Chemotherapeutics are limited in their ability to cross
the blood–brain barrier (BBB) and consequently have little
efficacy in the treatment of brain metastases [7,13].
The local BBB associated with brain tumors is referred
to as the blood–tumor barrier (BTB) [14–17]. Several
studies have described significant heterogeneity in the
permeability of the BTB associated with individual brain
metastases [18,19]. Lockman et al. [18] showed that the
BTB of breast cancer brain metastases in mice exhibited
significant heterogeneity in permeability to dextran and
that permeability was unrelated to the size or to the
morphology of the metastases. Zhang and colleagues
examined brain metastases produced by eight human
cancer cell lines and reported that permeability to sodium
fluorescein varied depending on the tumor type and was
related to tumor morphology and size. Small compact
metastases were not permeable until they reached
0.2 mm2 and diffuse metastases were permeable only
when they coalesced to form a large mass [20]. These
studies were based on ex-vivo experiments conducted at
specific endpoints and provide only a snapshot of the
permeability status of metastases. MRI has also been
used to evaluate BBB integrity in vivo [21–23].
Gadolinium contrast agents such as gadopentetic acid
(Gd-DTPA) are routinely used in MRI to demonstrate
BBB breakdown [19,24–27]. Gadolinium is impermeable
to an intact BBB; however, extravascular enhancement in
MRI images after administration of Gd-DTPA is indi-
cative of a leaky BBB or increased permeability [28].
Percy et al. [19] used Gd-DTPA-enhanced MRI to
Original article 127
0960-8931 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/CMR.0000000000000136
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
evaluate BBB permeability and tumor burden in a mouse
model of breast cancer metastasis to the brain.
Only a few studies have carried out a longitudinal analysis
of melanoma brain metastases [29–31], yet to date none
have performed a detailed assessment of enhancing and
nonenhancing melanoma brain metastases with respect to
the factors influencing the changes in permeability. In this
study, longitudinal MRI was used to characterize a clini-
cally relevant model of melanoma brain metastases; the
BTB integrity and the total metastatic burden were
determined at four time points during the development of
brain metastases. Factors such as volume, brain location,
and age were investigated to determine their potential
influence on the changes in metastatic tumor permeability.
Materials and methods
Animal model
The human metastatic melanoma A2058 cell line was
purchased from the American Type Culture Collection and
cultured at 37°C in a 5% CO2 atmosphere in Dulbecco’s
Modified Eagle Medium containing 10% fetal bovine
serum (Gibco; Invitrogen, Burlington, Ontario, Canada).
Nude female mice (nu/nu) that were 6–8 weeks old were
used (Charles River Laboratories, Saint Constant, Quebec,
Canada) in accordance with an approved animal use pro-
tocol from the Western University – University council on
animal care. A 28.5 gauge insulin syringe was used to inject
100 μl of 50 000 A2058 cells (contained in Hank’s balanced
salt solution) into the left ventricle of the beating mouse
heart [19,32]. Mice were weighed and monitored weekly
for signs of health or sickness.
Magnetic resonance imaging
Mice were imaged using a 3T GE MR750 MRI clinical
scanner (General Electric, Milwaukee, Wisconsin, USA)
equipped with a custom-built gradient coil insert (maximum
gradient coil strength=500mT/m and peak slew rate=3000
T/m/s) and a solenoid radiofrequency (RF) mouse head coil
(inner diameter=1.5 cm). Before scanning, mice were anes-
thetized with 3% isofluorane for induction and 1–2% iso-
fluorane for maintenance (in 100% oxygen). For longitudinal
analysis, two imaging sequences were used on consecutive
days at four different time points after cell injection: days 21/22,
days 24/25, days 27/28, and days 30/31. On the first day, before
scanning, mice were injected intraperitoneally with 200μl of
undiluted Gd-DTPA (Magnevist; Schering, Whippany, New
Jersey, USA). T1-weighted spin echo (T1wSE) images were
acquired 60min after Gd-DTPA injection using the following
parameters: resolution=156×156×500μm, TR/TE=600/
20ms, signal averages=12, receiver bandwidth=±15.63 kHz,
and scan time=15min. On the second day, balanced steady-
state free precession (bSSFP) images were acquired using the
following parameters: resolution 100×100×200μm, TR/
TE=8/4ms, flip angle=35°, signal averages=2, receiver
bandwidth=±41.67 kHz, RF phase cycles=8, and scan
time=30min.
Image analysis
OsiriX image software (open source) was used for image
visualization and analysis. bSSFP images were used to
count the number of metastases and measure the
volumes of individual metastases within the whole brain
at each time point. Volume measurements were obtained
using a manual trace method where tumor borders were
manually outlined in each image slice and a final algo-
rithm was computed to obtain a three-dimensional tumor
volumetric measurement (mm3). T1wSE images were
used to determine which metastases were enhanced
(leaky BTB) after Gd-DTPA administration. T1wSE
images were viewed alongside bSSFP images at all four
imaging time points. Enhancing metastases were defined
as those with an increase in signal intensity compared
with the surrounding mouse brain tissue, in regions in
which bSSFP revealed a metastasis. Metastases classified
as nonenhancing were not visible on T1wSE images but
were visualized on bSSFP images. Parenchymal metas-
tases were defined as those located within and sur-
rounded by brain tissue, as well as having no contact with
the surfaces of the brain. Metastases classified as
meningeal were described as having at least one side
adjacent to the surface of the brain. Verification of
meningeal metastases was performed using a reslice tool
in OsiriX, which further classified meningeal metastases
as originating from either the pia (leptomeninges) or dura
mater according to the bSSFP MRI appearance.
Histology
After Gd-DTPA permeability analysis, mice (n= 4) anes-
thetized with 3% isofluorane received 1.5mg Dextran
Texas Red (Invitrogen/Molecular Probes, Eugene,
Oregon, USA) by tail vein injection. After 20min, the mice
were perfused with 4% paraformaldehyde and their brains
were removed and placed overnight in increasing con-
centrations of sucrose (10, 20, and 30%) for cryoprotection.
Mice brain tissues were embedded in Tissue-Tek optimal
cutting temperature medium (Sakura, Saskatchewan,
Canada). Frozen sections were cut with a cryostat (Leica
Microsystems, Concord, Ontario, Canada) at 20 μm. Mice
(n= 3) that did not receive dextran perfusions were per-
fused only with 4% paraformaldehyde. Their brain tissues
were embedded in paraffin and cut with a microtome
(Leica Microsystems) at a thickness of 10 μm, followed by
hematoxylin and eosin (H&E) staining. Dextran leakage,
visualized as red fluorescence (595 nm excitation, 615 nm
emission), was imaged using a fluorescence Zeiss Axio
Imager A1 microscope (Zeiss, Oberkochen, Germany) with
a Retiga Exi (QImaging, Surrey, BC, Canada) digital
camera for capturing images. Image Pro Plus software
(Media Cybernetics, Inc., Rockville, Maryland, USA) was
used for histological image editing.
Statistical analysis
Statistical analyses were carried out using GraphPad
Prism software (GraphPad Software, Inc., La Jolla,
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California, USA). Comparison of groups (enhancing vs.
nonenhancing brain metastases) at each time point was
performed using the Kruskal–Wallis test, followed by the
post-hoc test, Dunn’s multiple comparison test. The
level of statistical significance was P less than 0.05.
Results
In-vivo magnetic resonance imaging of melanoma brain
metastases
To characterize melanoma brain metastasis a cell injection
of 50 000 A2058 human metastatic melanoma cells was
delivered intracardially to the mouse brain. This cell
injection number produced between three and 23 brain
metastases per animal. Meningeal and parenchymal
melanoma brain metastases were observed (Fig. 1a and c).
The appearance of meningeal and parenchymal metas-
tases in bSSFP images (Fig. 1a and c) was slightly or
moderately hyperintense (increase in signal intensity).
The corresponding hematoxylin and eosin stain (H&E)
histological images (Fig. 1b and d) showed meningeal and
parenchymal metastases to be hypercellular lesions.
Hemorrhage was also visualized on bSSFP MRI and H&E
staining. The development of hemorrhage (region of low
signal intensity) was observed on bSSFP images
(Fig. 2b–d, yellow arrows). At day 25, signal loss (Fig. 2b)
was observed within a parenchymal metastasis; over time,
this signal hypointensity increased in size. At day 31,
visualization of the tumor was obscured by the blooming
artifact (Fig. 2d) due to the accumulation of super-
paramagnetic species. H&E staining (Fig. 2f and g)
revealed the presence of associated hemorrhage within the
parenchymal metastasis; hemorrhage is very common in
melanoma brain metastases in clinical practice. An iso-
intense (same contrast as background brain tissue) par-
enchymal metastasis was inconspicuous (Fig. 2a–d, blue
arrows) on bSSFP scans but was easily identified on H&E
histological images (Fig. 2e, green arrow).
During longitudinal studies, bSSFP MRI enabled early
detection of small nonenhancing melanoma brain metas-
tases. An example of the sensitivity of bSSFP toward small
nonenhancing metastases is seen in Fig. 3. A single metas-
tasis (Fig. 3c) was visible on bSSFP images at day 25, but not
at day 24 with T1wSE images obtained after Gd-DTPA
administration (Fig. 3a). The nonenhancing metastasis visi-
ble at day 25 (Fig. 3c) was visible as an enhancing metastasis
at day 27, after Gd-DTPA administration (Fig. 3b). At day
28, this metastasis had increased in size. During longitudinal
analysis, we observed in most cases that, at the early time
point, metastases were nonenhancing after Gd-DTPA
administration, and thus they are not associated with a dis-
rupted BTB; however, they were detectable on bSSFP
images.
Fig. 1
Mouse brain bSSFP MRI and whole-brain histology for A2058 melanoma brain metastases. (a, c) Representative bSSFP images of melanoma brain
metastases (yellow arrows). (a) Meningeal metastases (yellow arrow) appear hyperintense relative to the surrounding brain tissue. A signal void (black dot;
hypointense signal) is also detected near the middle of the brain in the bSSFP image. (b) H&E-stained histological tissue section showing a hypercellular
meningeal metastasis toward the top of the mouse brain. (c) Parenchymal metastases (yellow arrows) appear hyperintense in the brain parenchyma.
(d) H&E-stained histological tissue section showing three parenchymal brain lesions; two metastatic parenchymal lesions are hypercellular and appear to
be strongly stained with H&E, whereas the other (near the ventricle) appears to be only faintly stained with H&E, which could be due to early stages of
tumor development. Scale bars=250 μm. bSSFP, balanced steady-state free precession; H&E, hematoxylin and eosin.
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The melanoma brain metastases did not all show
enhancement after Gd-DTPA administration at the same
time point; rather, they typically changed from non-
enhancing to enhancing from one scanning time point to
the next. In Fig. 4, T1wSE images obtained after Gd-
DTPA administration (Fig. 4a–d) and bSSFP images
(Fig. 4e–h) of a mouse brain have been shown. On day
22, a metastasis was visible on the bSSFP image (Fig. 4e);
however, it did not appear to be enhancing after Gd-
DTPA administration until day 24 (Fig. 4b). At day 27, a
new enhancing metastasis was visible near the top of the
brain (Fig. 4c) and was also visible on bSSFP images
(Fig. 4g and h). At day 31, a third metastasis was detected
by bSSFP (Fig. 4h); however, it was not yet enhancing
after Gd-DTPA administration. In general, the number
of enhancing metastases in our longitudinal MRI study
increased over time. An exception was the case of one
mouse that had only nonenhancing brain metastases.
Volume, location, and age of enhancing and
nonenhancing brain metastases
Factors such as volume, brain location, and age of a
metastasis were studied to determine whether they had
an effect on the permeability of metastases. A wide range
of volumes were measured for enhancing and non-
enhancing metastases at each time point (Fig. 5a).
Fig. 2
Day 22 Day 25
Day 28 Day 31
1 9
14 19
(a) (b)
(c) (d)
(e) (f) (g)
Hypointense and isointense melanoma mouse brain metastases on bSSFP MRI with H&E histology. (a–d) Representative bSSFP images showing
the development of a parenchymal brain metastasis (yellow arrows) in the frontal brain region at four time points. A region of signal hypointensity (low
signal intensity) appears over time at the center of the parenchymal metastasis. This metastasis increased in size over time. (d) A blooming artifact
obscures visualization of the metastasis at day 31. (a–d) An isointense metastasis (blue arrows) remains inconspicuous in the bSSFP images at all
four time points. (e) The isointense metastasis in the bSSFP image is identified in H&E histology (green arrow), scale bar=250 μm. (f) Inset of
metastasis enclosed by a black square in (e) showing the presence of hemorrhage in the H&E-stained section, scale bar=400 μm. (g) H&E
histological image obtained at high-power magnification (×40) showing the presence of blood (white arrows) nested in between and surrounding
A2058 melanoma cells, scale bar=650 μm. Numbers near the lower right corner of each bSSFP image (a–d) refer to the total metastatic burden at
each time point. bSSFP, balanced steady-state free precession; H&E, hematoxylin and eosin.
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Fig. 3
Day 24 Day 27
T1wSE + Gd
bSSFP
Day 25 Day 28
(a) (b)
(c) (d)
Early detection of nonenhancing melanoma brain metastases using bSSFP. Representative T1wSE images obtained after Gd-DTPA administration
and bSSFP images in a melanoma brain metastasis mouse model. (a) At day 24, enhancing metastases are not visible after Gd-DTPA administration,
but at day 25, a nonenhancing metastasis (yellow arrow) is visible at the early time point using bSSFP MRI. (b) An enhancing metastasis is now visible
(yellow arrow) at day 27 after Gd-DTPA administration. (d) At day 28, the metastasis has increased in size. bSSFP, balanced steady-state free
precession; Gd-DTPA, gadopentetic acid.
Fig. 4
Day 21 Day 24 Day 27 Day 30
Day 22 Day 25 Day 28 Day 31
(a) (b) (c) (d)
(e) (f) (g) (h)
Asynchronous appearances of enhancing and nonenhancing melanoma brain metastases. (a–d) Metastases do not all appear to be permeable to
Gd-DTPA at the same imaging time point. Often, they change from a nonenhancing tumor to an enhancing tumor over time. (e) A meningeal brain
metastasis (yellow arrow) was detected on bSSFP images at day 22 but was not permeable to Gd-DTPA at day 21. This metastasis was enhancing
after Gd-DTPA administration at the next imaging session, on day 24. At day 27, a new enhancing metastasis was visible near the top of the brain and
was also visible on bSSFP images. (h) At day 31, a third metastasis is detected by bSSFP, but it is not yet enhancing after Gd-DTPA administration.
Yellow arrows=metastases. bSSFP, balanced steady-state free precession. Gd-DTPA, gadopentetic acid.
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The volume data analyzed suggest that metastasis
volume is not a contributor toward changes in perme-
ability, as both small and large metastases were observed
as enhancing at days 24, 27, and 30 (Fig. 5a). For
instance, the smallest and largest enhancing metastases at
days 24, 27, and 30 were 0.0804 and 7.15 mm3, 0.204 and
26mm3, and 0.425 and 42.9 mm3, respectively. Overall,
the volumes of metastases increased over time. However,
there was no statistically significant difference (P< 0.05)
between the volumes of enhancing and nonenhancing
metastases at any time point.
Melanoma brain metastases within various regions of the
mouse brain (Fig. 5b–e) were also studied. We observed
that enhancing and nonenhancing metastases were dis-
persed throughout the brains of the mice. Brain location
did not have an effect on metastasis volume either, as
both large and small lesions were detected throughout
the brain (data not shown).
The age of a metastasis did not predict whether a
metastasis would become enhancing after Gd-DTPA
administration. In Fig. 5f, the patterns of enhancement
are illustrated. There are, for example, brain tumors
(i) that first appear as an enhancing metastasis and remain
as an enhancing metastasis (these are few in number);
(ii) that first appear as a nonenhancing metastasis and
then switch to an enhancing metastasis at a later imaging
Fig. 5
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Enhancement versus volume, brain region and age of metastases. (a) The volumes of enhancing and nonenhancing metastases increased over time.
A trend toward increasing volumes was observed. However, no statistical difference (P<0.05) in tumor volumes at each time point was evident.
Bars represent medians. (b–e) Representative bSSFP images showing enhancing and nonenhancing metastases in different brain regions.
(b, c) Enhancing metastases with their corresponding volumes in the (b) midbrain–hindbrain region and (c) the frontal region, respectively.
(d, e) Nonenhancing metastases with their corresponding volumes in (d) the olfactory–frontal region and (e) the frontal region. (f) Patterns of
enhancement over time for A2058 melanoma brain metastases. Each colored line and dot shown in (f) represents a different metastasis. Light blue
line=metastasis first detected as enhancing and which remained enhancing, pink line=metastasis that never enhanced. Light red, dark blue, and
dark purple lines=metastases that first appeared as nonenhancing but changed to enhancing at later time points. Red, green, and light purple
dots= late-appearing metastases that were nonenhancing. Hollow circles= enhancing metastases and solid circles= nonenhancing metastases.
bSSFP, balanced steady-state free precession.
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time point (these constitute the majority of brain
metastases); and (iii) that first appear as a nonenhancing
metastasis and remain as a nonenhancing metastasis
(these are more rare). In no case did we observe an
enhancing metastasis switch to a nonenhancing
metastasis.
Histology: in-vivo permeability versus ex-vivo
permeability
In-vivo permeability using Gd-DTPA contrast agent
(MW 590Da) was compared with ex-vivo permeability
using the Dextran Texas Red tracer (MW 3kDa). Gd-DTPA
was selected to assess the in-vivo BBB integrity as it is rou-
tinely used clinically to assess BBB integrity. The Dextran
Texas Red tracer was selected to assess ex-vivo permeability
and to compare our results with those of previously published
studies that have also used dextran to assess BBB integrity. In
Fig. 6a–d, an example of an enhancing metastasis is shown.
This metastasis is clearly visible on both bSSFP images and
those obtained on T1wSE after Gd-DTPA administration
(Fig. 6a and b). Red fluorescence microscopy (Fig. 6c) for this
enhancing metastasis showed evidence of permeability to
dextran. Dextran leakage was not homogeneous throughout
the enhancing metastasis, implying that some blood vessels
may be more permeable than others within this metastasis.
H&E histological images (Fig. 6d) for the enhancing metas-
tasis at day 31 showed a hypercellular mass comprising small
cell clusters. In Fig. 6e–h, an example of a nonenhancing
metastasis is shown. This brain metastasis is detected on the
bSSFP image but not on T1wSE images obtained after Gd-
DTPA administration. Red fluorescence microscopy (Fig. 6g)
for this nonenhancing metastasis showed small punctate
regions, confined to vessels, which were permeable to dex-
tran, suggesting that BTB regions within this nonenhancing
metastasis were not completely intact (Fig. 6g). H&E histo-
logical images for the nonenhancing metastasis (Fig. 6h)
showed less hypercellularity, which may indicate that this
tumor is in a relatively early stage of development.
Discussion
In the present study, we have characterized the appear-
ance and size of melanoma brain metastases using MRI.
This model of melanoma brain metastases recapitulates
many of the MRI and histological features of brain
metastases in melanoma patients. These features
include: (i) the presence of both parenchymal and
meningeal metastases, (ii) hemorrhage, (iii) three to 23
metastases in mice compared with one to 10 in patients,
(iv) variable MRI appearance, and (v) rapid growth.
Despite our ability to recapitulate much of what is seen in
humans, this model presents a limitation because of the
fact that the immune-compromised status of the mice
may limit the extrapolation of the model to humans. To
our knowledge, this is the first study to use 3 T MRI to
monitor the development of melanoma brain metastases
longitudinally. Metastasis and BTB permeability are
dynamic processes and hence longitudinal imaging is
essential to study the development of an altered BBB in
metastases.
This is the first report on the use of bSSFP to image
melanoma brain metastases. Brain metastases appeared
slightly or moderately hyperintense compared with the
surrounding brain tissue on bSSFP images, which have
contrast related to T2/T1. This could be due to the
degree of melanin present and/or hemorrhage, as melanin
and methemoglobin, a blood degradation product, both
affect the extent of T1 shortening (leading to variations
in signal hyperintensity). Occasionally there were
metastases that appeared hypointense, more often at late
time points, which were likely caused by the presence of
blood degradation products such as hemosiderin. Rarely,
we identified metastases that were isointense on bSSFP
images and were therefore inconspicuous, probably due
to simultaneous T1 and T2 shortening or the absence of
melanin. The variation in MRI appearances of melanoma
brain metastasis in our model is consistent with that
reported clinically and is based largely on the degree of
melanin and the presence or absence of hemorrhage
[33–36].
Our MRI approach allows us to investigate the whole-
brain metastasis burden (using bSSFP) and the perme-
ability status (using Gd-DTPA-enhanced T1wSE) of all
tumors and thus can be used for the in-vivo evaluation of
the response of gadolinium-enhancing and gadolinium-
nonenhancing metastases to treatment. There are two
important aspects of the BTB in brain metastases. The
first relates to tumor detection by MRI. A compromised
BTB allows the MRI contrast agent gadolinium to leak
into the tissue and this creates signal enhancement in
images that are sensitive to it. Clinically, gadolinium is
widely used for brain tumor detection. The fact that not
all metastases are leaky does not mean that all metastases
are detected by this conventional MRI approach. This
may also be true in human brain metastasis imaging.
bSSFP imaging may be a superior detection method.
Second, chemotherapies generally do not work for brain
metastases because they cannot cross the BTB. What is
important is that we understand more about how the
heterogeneity in the permeability of brain metastases is
related to drug efficacy. Chemotherapeutics may reach
the leakiest of brain tumors but we show here that a
significant number of melanoma brain metastases are
nonenhancing. Our MRI approach allows us to investi-
gate the whole-brain metastasis burden and the perme-
ability status of all tumors and can be used for the in-vivo
evaluation of the response of both gadolinium-enhancing
and gadolinium-nonenhancing metastases to treatment.
Others have reported heterogeneity in the permeability
of brain metastases. Zhang et al. [20] showed through
histological analysis that there was variability in the BBB
permeability of brain metastases generated in mice from
eight different human cancer cell lines (breast, colon,
In-vivo assessment of melanoma brain metastases Henry et al. 133
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Fig. 6
T1wSE + Gd bSSFP
Dextran H&E
H&E
T1wSE + Gd bSSFP
Dextran
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Comparison of in-vivo and ex-vivo permeabilities. (a, b) Representative T1wSE images obtained after Gd-DTPA administration and bSSFP images for
an enhancing A2058 melanoma brain metastasis (yellow arrows). (c) Ex-vivo permeability showing dextran leakage (red fluorescence) into the tumor
interstitial spaces; dextran leakage is not homogeneous throughout the lesion, as some areas have brighter fluorescence compared with other
regions. (d) H&E histological images showing a hypercellular morphology for the enhancing metastasis. (e, f) Representative T1wSE images obtained
after Gd-DTPA administration and bSSFP images for a nonenhancing A2058 melanoma brain metastasis. A metastasis is only visible in the bSSFP
image (f, yellow arrow); (e) no enhancing metastases are visible in the T1wSE images obtained after Gd-DTPA administration. (g) Ex-vivo permeability
histology showing small amounts of dextran leakage within the interstitial tissue; bright regions of dextran fluorescence appeared to be confined within
blood vessels. (h) H&E histology at day 31 showing little hypercellularity. A2058 melanoma cells also appeared to be more closely associated with the
cerebral vasculature, scale bars=320 μm. bSSFP, balanced steady-state free precession; Gd-DTPA, gadopentetic acid; H&E, hematoxylin and eosin.
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renal, and melanoma). Lockman et al. [18] demonstrated
that breast cancer brain metastases in nude mice showed
a range of values for passive permeability to the 3 kDa
tracer Texas red fluorescent dextran. This work was
followed up by an in-vivo MRI study conducted by Percy
et al. [19] at our laboratory. They showed that no
enhancing metastases were visualized at the early time
point with T1wSE using Gd-DTPA.
To understand what factors could be involved with
changes in permeability, the metastasis size, brain loca-
tion and age were investigated to observe whether they
had any influence on permeability. We found no rela-
tionship between location in the brain and enhancement
after Gd-DTPA administration. Neither did the age of
the metastases nor did the time between cell injection
and the imaging time point influence permeability status.
However, we cannot exclude the possibility that with
more time a ‘nonenhancing’ tumor may change to an
‘enhancing’ tumor. Furthermore, size of the metastases
increased with time but there was no significant differ-
ence in volumes assessed from MRI data of enhancing
and nonenhancing metastases at any imaging time point.
These findings are very similar to those previously
observed by Percy et al. [19] for brain metastases due to
breast cancer. Lockman et al. [18] also reported no clear
relationship between the diameter of the brain metas-
tases, measured by histological analysis, and the degree
of permeability to dextran. Historically, changes in the
integrity of the BTB have been associated with large
brain tumors (1–4 mm), which become oxygen and
nutrient deprived and develop angiogenic vessels [37,
38]. Our data, however, show that even very small
metastases may be leaky. Differences in the specific
tracer or contrast agent used, the cell lines, and the timing
of the interrogation of tumors may be possible reasons for
discrepancies between the results of our study and those
of others. Together, all of these studies reveal a complex
relationship between biological features of a brain
metastasis and BTB permeability.
Several mechanisms of tumor-associated vascularization
have been identified, which influence vascular perme-
ability in the brain [39]. The first is angiogenesis.
Angiogenesis is the development of new blood vessels
from pre-existing vasculature [39]. Vascular endothelial
growth factor (VEGF) is a potent angiogenic factor that
can also promote vasodilation of blood vessels, induce
vascular permeability, and mediate migration of endo-
thelial cells to form new blood vessel structures [40,41].
This neovasculature is known to be leaky, disorganized,
and tortuous [37,41,42]. In the brain, the neovasculature
is abnormal in structural components of the BBB
including tight junctions and the basement membrane
layer [37,42]. Another mechanism by which melanoma
cells acquire blood supply is vessel co-option. Vessel co-
option is the use of pre-existing blood vessels, whereby
cells are directly associated with and grow along blood
vessels; this mechanism of vascularization is quite com-
mon in brain tumors [42–45]. Finally, there is vasculo-
genic mimicry. This is where tumor cells line vascular
walls rather than endothelial cells [46,47]. The end
results are vessel-like networks that mimic normal or
embryonic-like vessel structures [39]. The term ‘vasculo-
genic mimicry’ was first introduced in 1999 and was first
described in melanoma, more specifically in uveal and
metastatic cutaneous melanomas, in which patterned
microvasculature consisting of networks and loops or
looping networks were observed [46,47].
Vessel co-option does not cause disturbance to the
endothelium of the BBB [21,24] and the barrier remains
intact. This might explain why some metastases in our
study did not enhance after administration of Gd-DTPA.
There is also the possibility that vasculogenic mimicry
can also be contributing toward the lack of enhancement
of brain metastases after Gd-DPTA administration. Van
der Schaft et al. [48] showed that melanoma tumors that
exhibited evidence of vasculogenic mimicry were rela-
tively unaffected by antiangiogenic treatments, suggest-
ing that tumor cell-lined vasculature was impenetrable or
unresponsive to angiogenic inhibitors.
Oliver et al. [49] have shown that VEGF secretions are
associated with the A2058 melanoma cell line, and
Leenders et al. [28] observed VEGF expression in
melanoma brain metastases that showed vessel co-option.
It is possible that VEGF secretion by melanoma cells co-
opted to blood vessels in the brain and VEGF-induced
angiogenesis may be simultaneously contributing to
leakiness of the BBB [28,37]. Angiogenesis, vessel
co-option, and vasculogenic mimicry [39,42–45,46,47]
may be occurring simultaneously and together could
influence or control the permeability status of individual
brain metastases.
Conclusion
Clinically, T1wSE with Gd-DTPA administration is the
gold standard for brain tumor imaging [36,50]. Findings
from our characterized, clinically relevant model reveal
that some metastases may go undetected on T1wSE
imaging and that using bSSFP imaging enables the
detection of nonenhancing brain metastases at early time
points. Additional longitudinal studies assessing the
molecular and biochemical properties of enhancing and
nonenhancing metastases will be an important factor in
understanding permeability behavior, disease progres-
sion, and variable responses of melanoma brain metas-
tases to treatments.
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